Business & Finance
Circassia acquires US rights to AstraZeneca's Tudorza and Duaklir
20 March 2017 -

UK speciality biopharmaceutical company Circassia Pharmaceuticals (LON:CIR) has agreed a transformative deal to acquire US commercial rights to two chronic obstructive pulmonary disease (COPD) products from AstraZeneca, the Pharmaceutical Technology website reported on Monday.

Under the terms of the USD230m agreement, Circassia Pharmaceuticals will obtain US commercial rights for Tudorza and Duaklir COPD products.

Tudorza and Duaklir are key components of AstraZeneca's global respiratory franchise. This collaboration will support their commercialisation in the US for the benefit of millions of COPD patients, said Mark Mallon, global product and portfolio strategy executive vice-president.

The value of the deal includes future royalties based on sales upon the commercialisation of Duaklir in the US, pending future approval.

In return, AstraZeneca will receive a minority stake in Circassia and complete ongoing development activities, continuing to manufacture and supply both medicines.

Tudorza is approved in the US and around 60 other countries, with total worldwide revenues reaching USD170m last year – of which USD80m was in the US.

Meanwhile, Duaklir is currently in the Phase II development stage for the treatment of COPD in the US. It has already been approved in 50 countries worldwide.

Login
Username:

Password: